Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2007

KineMed to Validate New Drug Applications for Merck KGaA

  • KineMed will collaborate with Merck Serono, a division of Merck KGaA, to discover new applications for drug candidates.

    KineMed’s pathway-based drug discovery and development technology identifies compounds that can modulate key metabolic pathways present in both preclinical animal models and in humans. By measuring real-time activity of drugs against these targeted pathways, the platform reduces development risk by selecting drug candidates with the best potential to demonstrate clinical efficacy and confirm desired drug activity in clinical studies, according to KineMed.

    KineMed will identify new therapeutic utility in in vivo preclinical models. Once a disease target is established for a selected drug candidate, KineMed and Merck KGaA will jointly determine the best development and commercialization path for the candidates being studied.

    KineMed will receive an upfront payment, milestones fees, and royalties on products advanced with its technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »